Evidence map›Paper›PMID 41716569›Full record

ArticleEuropean urology open science2026

Surgical Technique and Perioperative and Postoperative Outcomes for Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Performed with the Hugo RAS Robotic Platform: First Large Case Series by the European Association of Urology Robotic Urology Section Scientific Working Group.

Simone Scuderi, Juhana Rautiola, Chiara Sighinolfi, Francesco Prata, Darko Bogdanovic, Francesco Tedesco, Ruben De Groote, Francesco Barletta, Frederiek D'Hondt, Edward Lambert and 18 more

Abstract read
In one paragraph

Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Simone ScuderiGianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Juhana RautiolaDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Chiara SighinolfiUrology Unit, IRCCS A. Gemelli Hospital, Catholic University of the Sacred Heart, Rome, Italy.
Francesco PrataDepartment of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Darko BogdanovicDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Francesco TedescoDepartment of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Ruben De GrooteAzorg Hospital, Aalst, Belgium.
Francesco BarlettaGianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Frederiek D'HondtAzorg Hospital, Aalst, Belgium.
Edward LambertAzorg Hospital, Aalst, Belgium.
Joan PalouDepartment of Urology, Fundació Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain.
Andrea GallioliDepartment of Urology, Fundació Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain.
Giuseppe BasileGianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Donato CannolettaGianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Francesco PellegrinoGianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Ugo FalagarioDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Giuseppe CarrieriDepartment of Urology and Renal Transplantation, University of Foggia, Foggia, Italy.
Giorgio GandagliaGianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Alberto BrigantiGianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Francesco MontorsiGianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Rocco PapaliaDepartment of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Markus AlyDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Olof AkreDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Bernardo RoccoUrology Unit, IRCCS A. Gemelli Hospital, Catholic University of the Sacred Heart, Rome, Italy.
Alexander MottrieAzorg Hospital, Aalst, Belgium.
Alessandro LarcherGianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Alberto BredaDepartment of Urology, Fundació Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain.
Peter WiklundDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: The Hugo RAS robotic platform has shown promising results for urological surgical procedures, but there is a lack of data on robot-assisted radical cystectomy (RARC). Our aim was to describe the surgical technique for RARC performed with the Hugo RAS robot and to assess perioperative and postoperative outcomes. Methods: We identified 29 patients who underwent RARC with lymph node dissection and intracorporeal urinary diversion (IUD) performed with a Hugo RAS robot at five centers between February 2023 and June 2024. An intraoperative video was recorded to show the surgical technique. Data for intraoperative and 90-d postoperative complications were collected according to the European Association of Urology recommendations. Key findings and limitations: In the cohort of 29 patients, 21 (72%) were male and 19 (68%) had a muscle-invasive tumor on clinical evaluation. Nerve-sparing surgery was performed in four men and pelvic organ-preserving procedures in six women. Orthotopic diversion was performed in 14 patients (48%). The median hospital stay was 7 d and median operative time was 279 min. Four patients (14%) had intraoperative complications and 12 (41%) had an any-grade postoperative complication, of which three (10%) were of high grade (Clavien-Dindo grade >2). The most common complications were urinary tract infection ( Conclusions and clinical implications: Our results demonstrate the safety and feasibility of the Hugo RAS robotic platform in performing RARC with IUD. Perioperative and postoperative outcomes were comparable to those reported for established robotic systems, without the need for platform-specific modifications. Patient summary: We looked at bladder cancer surgery using the new Hugo RAS robotic system in a group of 29 patients. The surgery was safe and effective, with outcomes similar to those seen with more established robotic systems. Our results suggest that this new robot is a reliable surgical option for bladder removal.

Indexed as

Bladder cancerComplicationsPerioperative outcomesRadical cystectomyRobotic surgery

Identifiers

PMID41716569
PMCPMC12914454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.